QLT initiates phase II study of punctal plug drug delivery system for glaucoma & ocular hypertension

01-Apr-2008 - QLT Inc. announced the initiation of patient recruitment into its "CORE" study, a phase II trial being conducted by QLT's wholly-owned subsidiary, QLT Plug Delivery, Inc. ("QPD"), to evaluate the preliminary efficacy and safety of its latanoprost punctal plug delivery system for the treatment of ...

Eligard six-month formulation successfully completes European approval procedure

03-Sep-2007 - QLT USA, Inc., a subsidiary of QLT Inc., announced that the European approval procedure for the Eligard(R) 45 mg six-month formulation was successfully completed. Launch of this formulation in 23 European countries is expected to follow the implementation of this positive decision in each of the ...

QLT announces positive findings from Phase IV G6PD deficiency study for Aczone(TM) in acne

09-Nov-2006 - QLT Inc. announced positive results of a Phase IV clinical trial of Aczone(TM) in more than 50 patients with G6PD deficiency that was performed to meet a post-approval commitment requested by the FDA. The purpose of this study was to gather more information about the safety of Aczone, a ...

QLT Updates on the U.S. Eligard Patent Litigation

Temporary Suspension of Eligard Sales in the U.S. by Sanofi-Synthelabo

08-Mar-2006 - QLT Inc. announced that the Court of Appeal has informed QLT USA, Inc. that the injunction against promoting, manufacturing, selling and offering for sale Eligard(R) has been stayed pending its decision to grant a permanent stay of the injunction. Also, QLT USA's marketing partner for Eligard in ...